Buy, Sell Or Hold: HDFC Bank, Sun Pharma, Rallis India, Trent | Ask Profit
HDFC Bank left its position unchanged.
· NDTV Profit
Market experts shared their insights on fundamentals and technical levels for key stocks.
The analysis
Against that, the stock is -1.5% on the day at ₹692.20, and has returned -14.6% over three months. It sits 31% below its 52-week high, which means a good deal of bad news was already in the price. The banks sector has moved -1.7% over the same period, so HDFC Bank is running 12.9 points behind its peers.
For HDFC Bank, the question is how much of this is already reflected in the price and how much re-rates the banks peer set alongside it.
Market context
- The company directly in focus is HDFCBANK.
- Sector exposure: Banks, Pharma & Healthcare.
In this story
Related coverage
Anup Bagchi vs Sashidhar Jagdishan: How HDFC Bank’s incoming CEO pay compares with his predecessor
INR vs USD: Rupee near 97/dollar; how TCS, Sun Pharma, Tata Steel, SRF may gain from weaker currency? Experts explain
Banks vs NBFCs: Which stocks could benefit as RBI set to hike rates for the first time in 3 years?
Gold extends slide to ₹1.48 lakh per 10 gm in Delhi amid weak demand
Sun Pharma to consider ₹15,000 crore NCD issue; board meeting on 12 October